Main navigation
Search Results
-
-
Press release - 18/12/2023 Researchers discover novel antibiotic substance from the human nose
For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose -
Press release - 05/01/2024 How memories are formed in the brain – a new role for the internal compass
University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-memories-are-formed-brain-new-role-internal-compass -
Press release - 08/01/2024 Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor
Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv -
Press release - 03/01/2024 Reprogrammed fat cells support tumor growth
Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-fat-cells-support-tumor-growth -
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential
More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential -
Press release - 04/01/2024 Key player in viral heart inflammation discovered
Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered -
Press release - 15/01/2024 Maturation instead of cell death: Defective signalling pathways disrupt immune cell development
Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.
https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development -
Event - - 58th Annual Conference of the German Society for Biomedical Engineering (BMT 2024)
Basel / Muttenz, Switzerland, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/58th-annual-conference-german-society-biomedical-engineering-bmt-2024 -
Press release - 10/01/2024 MedTech Company KARL STORZ Acquires British AI Specialist Innersight Labs
The family-owned MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/medtech-company-karl-storz-acquires-british-ai-specialist-innersight-labs -
Press release - 18/01/2024 Indicator for liver health status identified
A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified -
Press release - 02/02/2024 University of Stuttgart successful with cluster draft proposals
The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-stuttgart-mit-clusterskizzen-erfolgreich -
Press release - 06/02/2024 New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff -
Press release - 02/02/2024 Epigenetic status determines metastasis
Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung -
Press release - 31/01/2024 Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive
A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver -
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions
Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions -
Press release - 17/01/2024 Immatics Announces Pricing of $175 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering -
Neurosciences - 28/02/2024 Mesh microelectrode arrays: research with brain organoids on a new level
How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.
https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level -
Event - 2nd Biointelligence Congress in Stuttgart
Stuttgart (Germany), Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/2nd-biointelligence-congress-stuttgart -
Press release - 12/02/2024 AI-supported image analysis: metrics determine quality
How well do the algorithms used in the AI-supported analysis of medical images perform their tasks? This depends to a large extent on the metrics used to evaluate their performance. An international consortium led by scientists from the German Cancer Research Center and the National Center for Tumor Diseases has compiled the knowledge available worldwide on the specific strengths, weaknesses and limitations of the various validation metrics.
https://www.gesundheitsindustrie-bw.de/en/article/news/ai-supported-image-analysis-metrics-determine-quality -
Press release - 22/02/2024 A new approach to recording cellular activities
In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities -
Press release - 04/03/2024 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value
https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million -
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer
Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.
https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer -
Press release - 07/02/2024 The unexpected long-term consequences of female fertility
The constant remodeling of the organs of the female reproductive tract during the reproductive cycle leads to fibrosis and chronic inflammation over the years. Scientists from the German Cancer Research Center (DKFZ) have now uncovered these unexpected long-term consequences of female reproductive function in mice. The results have been published in the scientific journal CELL.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/die-unerwartete-auswirkung-der-weiblichen-fortpflanzungsfaehigkeit -
Press release - 15/02/2024 Modelling the spread of diseases
Computer scientists from the Cluster of Excellence Collective Behaviour developed a model, that explains how collective scenarios such as diseases may proceed.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/modelling-spread-diseases